How do you approach molecular testing in patients with gastro-esophageal cancers?
Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving standard of care chemotherapy?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
Her2 is certainly more of a binary situation. Tumors that are Her2 positive (defined as IHC 3+ or IHC 2+ and FISH +ve) benefit from trastuzumab + chemotherapy, while there are no data to support it for tumors that are Her2 negative (IHC 0/1 or IHC 2+ and FISH -ve).
So, Her2 positive tumors should ab...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · The Oncology Institute of Hope and Innovation
Answered on
Yes for HER2
There is only evidence to show benefit in first-line setting with the addition of trastuzumab. “Patients with HER2 3+ by IHC benefit most with trastuzumab. And some can live a very long time, like, 12 and 13 years” as per Jaffer A. Ajani, M.D at MDAH, so clearly there is a long term bene...
Join for free or sign in to see the full answer